Join Our

Online Banking

Top Ten

Online Stock Trading

Bulletin Board

Stock Market Quotes

Gifts, Shopping

Pink Sheets

Page Builder

CME Globex2 Session

Live Chat Online Trading

Charts & Charting

Currency Rates

Free Auto-refreshin g Custom Pages!


Stock Picks

Real-time News Pages

Internet Lingo

Investment Books

Links Worlds Largest

Stock Quotes


Market Makers A-Z

Message Boards

News and Charts

Online Brokers W/ Phone Numbers

Options Information

Complete listing OTCBB Issues

Overseas Markets

Penny Stocks

S&P Fair Value

SI People & Subject

Site Map

Slang, Internet

Stock Markets

World Markets


Active Stocks


Privacy Policy

Affiliate Programs


NASCAR Schedule

PGA Schedule





Nuvo Pharmaceuticals Inc. Presentation Now Available for On-Demand Viewing


Company invites individual and institutional investors as well as advisors to log-on to to view presentation

MISSISSAUGA, Canada, April 16, 2018 /PRNewswire/ -- Nuvo Pharmaceuticals Inc. (OTCQX: NRIFF, TSX:NRI), based in Canada, focused on healthcare products and pharmaceuticals, today announced that the April 11th presentation from Jesse Ledger, Nuvo's President & CEO is now available for on-demand viewing at


Nuvo Pharmaceuticals Inc.'s presentation will be available 24/7 for 90 days. Investors and advisors may download shareholder materials from the "virtual trade booth" for the next three weeks.

  • In January 2018, the Company's wholly owned subsidiary, Nuvo Pharmaceuticals (Ireland) Limited (Nuvo Ireland) acquired the U.S. product and intellectual property rights to Resultz from Piedmont Pharmaceuticals LLC (Piedmont). Resultz was cleared as a Class 1 medical device by the U.S. Food and Drug Administration (FDA) in May 2017 and has not yet been commercially launched in the U.S. Nuvo anticipates commercializing Resultz in the U.S. through a licensing partner and has already initiated discussions with potential licensees.

  • In December 2017, the Company acquired the global, ex-U.S. product and intellectual property rights to Resultz from Piedmont. The transaction included existing royalty streams in France, Spain, Portugal, Belgium, Ireland and the United Kingdom, Canada, Russia, Australia, and Israel which are generated from a network of existing global licensees and license agreements that were assumed by Nuvo.

  • In December 2017, the Company entered into a license and distribution agreement with Gebro Pharma AG for the exclusive right to register, distribute, market and sell Pennsaid 2% in Switzerland and Liechtenstein.

  • In November 2017, the Toronto Stock Exchange (TSX) approved the Company's notice of intention to make a normal course issuer bid for a portion of its outstanding common shares as appropriate opportunities arise from time-to-time. Pursuant to the notice, Nuvo is authorized to acquire up to a maximum of 919,819 of its common shares, or approximately 10% of the public float of 9,198,191 as of November 30, 2017, for cancellation over the next 12 months. Nuvo believes that the repurchase of a portion of outstanding common shares is an appropriate use of available cash and is in the best interest of Nuvo and its shareholders.

  • On November 28, 2017, the Company's common shares commenced trading on the OTCQX® market in the United States under the symbol "NRIFF". Nuvo's common shares will continue to trade on the TSX under the symbol "NRI".

Learn more about the event at

About Nuvo Pharmaceuticals Inc.
Nuvo (TSX: NRI; OTCQX: NRIFF) is a global commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities.  Nuvo has four commercial products that are available in a number of countries: Pennsaid® 2%, Pennsaid, Resultz® and the heated lidocaine/tetracaine patch.  Nuvo manufactures Pennsaid 2% for the U.S market, Pennsaid for the global market and the bulk drug product for the HLT Patch at its FDA, Health Canada and E.U. approved manufacturing facility in Varennes, Québec.  The Company's focus is to maximize the value of Pennsaid 2% and Resultz through out-licensing to commercial partners in international markets and identifying new opportunities to acquire additional, accretive, late-stage products or businesses to further diversify the Company's existing product portfolio.  For additional information, please visit

Since 2010,, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.


Cision View original content with multimedia:

SOURCE Nuvo Pharmaceuticals Inc.

Back to top

RELATED LINKS  Links  Search   Disclaimer  About Us Advertising

© 1995, 1996, 1997, 1998,1999, 2000, 2001 All rights reserved.